News
At Argent BioPharma, our mission is to revolutionize healthcare through pioneering innovation.
We go beyond traditional disease management by exploring the intricacies of the immune system and harnessing cutting-edge technologies in our research and development endeavors.
Through our commitment to advancing medical science, we aim to reshape the landscape of global healthcare by addressing unmet needs and offering hope to underserved populations worldwide.
Our vision encompasses becoming a leading biopharmaceutical company renowned for groundbreaking medical treatments. By embracing NanoPolyPharmacology, we strive to introduce impactful solutions that elevate standards within the life sciences industry. Our dedication extends to ensuring accessibility to innovative therapies for communities overlooked by conventional medical approaches, thereby bridging healthcare disparities on a global scale.
As we progress on this ambitious path, we invite you to follow our journey and be a part of a transformative shift in healthcare. At Argent BioPharma, we’re not just changing treatments; we’re changing lives.
KEY PEOPLE
RELATED STOCKHEAD STORIES
Health & Biotech
This fundie reckons MGC Pharma can soar well over 3x current share price
News
Here’s what CEOs are hoping to change with their New Year’s resolutions for 2022
News
Waiting for 2022? Here’s a bunch of books CEOs are reading during the holiday break
News
CEOs look ahead to three things they’re hoping for in 2022
Health & Biotech
MGC Pharma pilots COVID-19 supplement, expects to benefit millions
News
CEOs look back and share their company highlights from 2021
News
CEOs look back and share the most important lesson they learnt in 2021
Health & Biotech
What you’ve been vaping for: MGC Pharma now has the first-ever Cannabinoid vape available as an unapproved therapeutic good for use in Australia
Health & Biotech
MGC Pharma secures $10m capital raise from US and UK investors to advance development for its lead drug candidate, CimetrA
Health & Biotech
As Biotron more than doubles on promising COVID results, which other ASX stocks are working on treatments?
Health & Biotech
MGC Pharma set for best half-yearly results after delivering ArtemiC order in Europe
Health & Biotech
MGC Pharma US partnership validated after receiving first payment for US$24m order of CimetrA
Health & Biotech
ASX Health Stocks: Paradigm rockets 21pc after getting FDA nod, Memphasys up 31pc on imminent launch
Health & Biotech
MGC Pharma opens new production facility in Malta, now set to ramp up sales of CimetrA
Health & Biotech
ASX Health Stocks: Intelicare jumps 35pc on AI in-home sensor tech contract for seniors
Health & Biotech
With record growth in 2021, MGC Pharma’s Q1 trading update confirmed it’s laid the foundation for a global expansion
Health & Biotech